MMP9 and stroke disorder: We demonstrated MMP-9 activation and neurovasculature impairment in stroke, and showed the ability of SB-3CT to inhibit MMP-9 activity in vivo, which resulted in maintenance of laminin, antagonism of pericyte contraction and loss, and preservation of laminin-positive pericytes and endothelial cells.